Showing 6501-6510 of 9147 results for "".
- Early Data Presented for Celotres™ for Keloid Scarshttps://practicaldermatology.com/news/20120224-early_data_presented_for_celotres_for_keloid_scars/2459866/Results from Halscion, Inc.'s KLEAR Study, which evaluated the initial safety and efficacy of Celotres™ in the treatment of keloid scars adjunctive to surgical excision, show a significant reduction (p=0.0110) in keloid recurrence, as compared to scientific literature, following a single treatment o
- Health Canada Approves BMS' Yervoy for Melanomahttps://practicaldermatology.com/news/20120208-health_canada_approves_bms_yervoy_for_melanoma/2459869/Health Canada approved Yervoy (ipilimumab 3mg/kg, Bristol-Myers Squibb) for the treatment of unresectable or metastatic melanoma in patients who have failed or do not tolerate other systemic therapy for advanced diseas
- New Rosacea Gel Coming Soonhttps://practicaldermatology.com/news/20120202-new_rosacea_gel_coming_soon/2459871/SkinCeuticals will soon unveil its Redness Neutralizer, a lightweight gel cream that prevents redness by targeting environmental triggers of inflammation leading to the onset of rosacea. Formulated wi
- Laser for Oncychomycosis Clearedhttps://practicaldermatology.com/news/20120202-laser_for_oncychomycosis_cleared/2459872/Recently FDA-cleared for the temporary increase of clear nail in patients with onychomycosis, Sciton's ClearSense handpiece provides optimum laser delivery for JOULE treatment to safely provide effective treatment for ski
- Paper: AI Gains Ground in Cosmetic Dermatology Workflowshttps://practicaldermatology.com/news/paper-ai-gains-ground-in-cosmetic-dermatology-workflows/2486551/A recent review in Dermatology and Therapy assessed the growing use of artificial intelligence (AI) across aesthetic dermatology, with the authors reporting increased adoption and highlighting its use in many aspects of prac
- Icotrokinra Shows Sustained Skin Clearance Through 52 Weeks in Psoriasishttps://practicaldermatology.com/news/icotrokinra-shows-sustained-skin-clearance-through-52-weeks-in-psoriasis/2486494/New 52-week data presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting highlight the sustained efficacy and safety of icotro
- Bimekizumab Shows Durable Psoriasis Clearance and 3-Year HS Controlhttps://practicaldermatology.com/news/bimekizumab-shows-durable-psoriasis-clearance-and-3-year-hs-control/2486394/New analyses from the BE RADIANT and BE VIVID trials showed the durability of response with bimekizumab (Bimzelx; UCB) in treating plaque psoriasis, alongside positive long-term findings in hidradenitis suppurativa (HS). Resu
- Remibrutinib Data at AAAAI Suggests Potential Expansion Beyond CSUhttps://practicaldermatology.com/news/remibrutinib-data-at-aaaai-highlight-expanded-potential-beyond-csu/2485784/New data on the selective Bruton’s tyrosine kinase inhibitor remibrutinib (Rhapsido) is slated for presentation at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, to be held February 27 to March 2 in Philadelphia.
- Study Details Creation of First Patient Decision Aid for Adult ADhttps://practicaldermatology.com/news/study-details-creation-of-first-patient-decision-aid-for-adult-ad/2485671/A new paper details the development of a patient decision aid (PDA) designed to support shared decision-making for adults with moderate to severe atopic dermatitis (AD), unique in this instance for targeting previously addressed systemic treatment selection for ad
- 23-Gene Expression Profiling Accurately Classifies Pediatric Melanocytic Lesionshttps://practicaldermatology.com/news/23-gene-expression-profiling-accurately-classifies-pediatric-melanocytic-lesions/2485549/A 23-gene expression profiling assay accurately distinguished benign nevi from melanoma in pediatric patients, according to “23-GEP Accurately Distinguishes Between Melanocytic Nevi and Melanoma in Pediatric Melanocytic Neoplasms,” a poster by Drazen Jukic, MD, et al presented as part of the “Bes